Taxus Companies Clash With Conor Over European Paclitaxel Patent
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific and Angiotech Pharmaceuticals are attempting to block Conor Medsystems' use of clinical trial data that would support a European CE mark for the CoStar paclitaxel-eluting stent